Book Value per Share: NextCure (NXTC)

Graphic logo of NextCure (NXTC)

NextCure, Inc. (NXTC) maintains strong pricing power based on the uniqueness of the FIND platform targets. The fair book value per share reflects capital dynamics, with the latest value recorded as 2.98. Its status as a scientific pioneer ensures expert trust in the brand. A strategic focus on R&D and identifying ways to overcome tumor resistance confirms the relevance of the company's product pipeline.

NXTC: NextCure Corp Net Asset Value per Share 07/04/2022 - 10/27/2026

nextcure.com - analytical breakdowns and key metrics (NXTC)

- price and consensus price forecast:
Stock Quotes NextCure Corp|NXTC - Analyst Forecast Prices
- market capitalization data:
Market Capitalization NextCure, Inc.|NXTC - Real Price to Acquire Entire Company
- book capitalization data:
Net Assets per Single Share NextCure|NXTC - Total Stockholders' Equity|Market Value to Book Value Ratio nextcure.com|NXTC - Total Business Assets
- debt and liquidity data:
Total Debt to Capital NextCure, Inc.|NXTC - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity NextCure|NXTC - Company Cumulative Debt|Debt to Book Capitalization Ratio NextCure, Inc.
Fundamental company valuation:NXTC - NextCure Corp
Flagship merchandise of NextCure

High operating expenses at NextCure, Inc. (NXTC) during early-stage antibody trials are putting pressure on capital, making asset analysis critical. The trend in book value per share reflects the portion of net assets attributable to a single security, allowing for an assessment of reserve management efficiency and asset impairment risks within the high-risk biotechnology sector.

Competitor analysis for NextCure, Inc.

Accounting Value per Share ImmunityBio Corp IBRX|IMCR - Book Price of a Share|JANX (Janux Therapeutics) - Book Value per Share|RCUS (arcusbio.com) - Accounting Value per Share|Net Assets per Single Share ZYME (Zymeworks)|Net Asset Value per Share TNGX|Net Assets per Single Share Iovance IOVA|Equity per Share Immatics Biotechnologies (IMTX)|Xencor, Inc. - Book Value per Share|compasstherapeutics.com - Accounting Value per Share|REPL (Replimune) - Net Assets per Single Share|LYEL: Net Asset Value per Share|Innate Pharma, S.A. (IPHA) - Net Assets per Single Share|PYXS (Pyxis Oncology) - Net Assets per Single Share|Net Assets per Single Share CGEN (Compugen Ltd)|Net Asset Value per Share iobiotech.com|STRO: Book Value per Share|Book Value of One Share MiNK Therapeutics Inc. INKT|HOWL: Accounting Value per Share|IMMX - Net Asset Value per Share|Accounting Value per Share ALX Oncology Holdings (ALXO)|CUE - Accounting Value of a Share|pdsbiotech.com - Book Value per Share|SONN (Sonnet BioTherapeutics Holdings) - Net Assets per Share|Net Assets per Single Share MAIA|Accounting Value per Share LIMN|Net Assets per Single Share LVTX (LAVA Therapeutics N.V.)|Accounting Value per Share leaptx.com LPTX|Accounting Value per Share INTS (Intensity Therapeutics, Inc.)|Sensei Biotherapeutics Inc - Book Value per Share|Synthetic Biologics (TOVX) - Net Assets per Single Share|GRTS: Equity per Share|Net Assets per Single Share KA|Net Asset Value per Share neximmune.com|Turnstone Biologics Corp - Accounting Value per Share|Book Value of One Share Vaccinex Inc. (VCNX)|Accounting Value per Share Harpoon Tx